These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 18591714)

  • 1. Biosimilars: illustration of scientific issues in two examples.
    Wenzel RG
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S9-15. PubMed ID: 18591714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing two botulinum toxin type A formulations using manufacturers' product summaries.
    Wenzel R; Jones D; Borrego JA
    J Clin Pharm Ther; 2007 Aug; 32(4):387-402. PubMed ID: 17635341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of biosimilars for the future.
    Johnson PE
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S16-22. PubMed ID: 18591711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical applications of a new botulinum toxin.
    Hexsel D; Spencer JM; Woolery-Lloyd H; Gilbert E
    J Drugs Dermatol; 2010 Mar; 9(3 Suppl):s31-7. PubMed ID: 20361474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulary Selection Criteria for Biosimilars: Considerations for US Health-System Pharmacists.
    Griffith N; McBride A; Stevenson JG; Green L
    Hosp Pharm; 2014 Oct; 49(9):813-25. PubMed ID: 25477613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacist Substitution of Biological Products: Issues and Considerations.
    Li E; Ramanan S; Green L
    J Manag Care Spec Pharm; 2015 Jul; 21(7):532-9. PubMed ID: 26108377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new botulinum toxin potentially bioequivalent to onabotulinumtoxinA: are there any differences at all?
    Yang GH; Jung HH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):165-70. PubMed ID: 23301820
    [No Abstract]   [Full Text] [Related]  

  • 15. Utilizing data consortia to monitor safety and effectiveness of biosimilars and their innovator products.
    ; Baldziki M; Brown J; Chan H; Cheetham TC; Conn T; Daniel GW; Hendrickson M; Hilbrich L; Johnson A; Miller SB; Moore T; Motheral B; Priddy SA; Raebel MA; Randhawa G; Surratt P; Walraven C; White TJ; Bruns K; Carden MJ; Dragovich C; Eichelberger B; Rosato E; Sega T
    J Manag Care Spec Pharm; 2015 Jan; 21(1):23-34. PubMed ID: 25562770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Conversion ratio between different botulinum neuroprotein product in neurological practice].
    Orlova OR; Timerbaeva SL; Khatkova SE; Kostenko EV; Krasavina DA; Zakharov DV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9):132-141. PubMed ID: 29053134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
    Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
    MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical considerations for the development of biosimilars in oncology.
    Socinski MA; Curigliano G; Jacobs I; Gumbiner B; MacDonald J; Thomas D
    MAbs; 2015; 7(2):286-93. PubMed ID: 25621390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar biologic drugs: a new frontier in medical care.
    Geynisman DM; De Velasco G; Sewell KL; Jacobs I
    Postgrad Med; 2017 May; 129(4):460-470. PubMed ID: 28343424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.